Analysis of randomized clinical trials leading to new drug approvals in India and USA
Keywords:Randomized clinical trials, Investigational medicinal product, New drug approvals, India, USA
Background:To analyse the number of randomized clinical trials and subsequent new drug approvals in India and USA.
Methods: Data was collected for completed randomized clinical trials done by multinational in India and USA from www.clinicaltrials.gov during the period from 1/1/2009 to 31/08/2014 and the subsequent new drug approvals from 1/1/2010 to 31/10/2015 for India obtained from Central Drugs Standard Control Organization (CDSCO) (www.cdsco.nic.in.) website and for USA obtained from United States Food and Drug Administration (USFDA) (www.fda.gov) website. Results were measured in terms of percentage of completed randomized clinical trials for investigational medicinal products (IMP) leading to new drugs approvals in India and USA.
Results: A total of 163 randomized clinical trials fulfilled the eligibility criteria. Regrouping them for the same sponsor and IMP resulted in a total of 93 randomized clinical trials. In India, 13 drugs (13.93%) were approved by CDSCO, whereas in USA, 35 drugs (37.62%) were approved by USFDA out of a total of 93 randomized clinical trials. High number of randomized clinical trials were conducted for cancer (17.20%) while less number of randomized clinical trials were conducted for gastrointestinal conditions (3.22%).
Conclusions: This study revealed that, there exists a wide gap between the new drug approvals permitted by USFDA and CDSCO. Thus there is disparity in the number of clinical trials conducted and market availability of new drugs in India showing that India is lagging behind the USA in approval of new drugs. The regulatory authorities, investigators and institutional review boards should ensure the availability of new drugs in India after they have been researched in the population.
Yadav P, Jay Karan, Chaudhari M, Saxena D, Kantharia ND. Clinical trials registered in clinical trial registry of India: A survey. J Pharmacol Pharmacother. 2011;2(4):289-92.
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1).1996. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed 24 March 2016.
Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
Pandey A, Aggarwal A, Seth S, Maulik M, Bano R, Juneja A. Clinical trials registry-India: Redefining the conduct of clinical trials. Indian J Cancer. 2008; 45:79-82.
Gupta YK, Padhy BM. India's growing participation in global clinical trials. Trends Pharmacol Sci. 2011; 32:327-9.
Contract research to grow at a healthy clip: ICRA. The Hindu Business line 2012. Available at http://www.thehindubusinessline.com/industry-and-economy/article2091126.ece. Accessed on 24 March 2016.
India emerging as hub for clinical trials says ASSOCHAM. Clinuity. 2011 [Internet]. Available at http://www.clinuity.com/blog/2011/07/india-emerging-as-hub-for-clinical-trials-says-assocham. Accessed on 24 March 2016.
ClinicalTrials.gov. Available at www.clinicaltrials.gov. Accessed on 24 March 2016.
The central drugs standard control organization (CDSCO). Available at www.cdsco.nic.in. Accessed on 24 March 2016.
U.S. Food and Drug Administration. Available at www.fda.gov.in. Acessed on 24 March 2016.
DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-7.
Duley L, Antman K, Arena J. Specific barriers to the conduct of randomized trials. Clin Trials. 2008; 5(1):40-8.
World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at http://www.wma.net/e/policy/pdf/17c.pdf. Accessed on 24 March 2016.
Requirements for filing of application to market new chemical entities. India: central drugs standard control organization, 2014.